CLINICAL_TRIALS
trial_result
· 2018-04-23
Clinical Trial Update: CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) [Phase 2]
Summary
A Phase 2 trial investigating extended dosing of CAVATAK in patients with advanced melanoma (Stage IIIc/IV) has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Viralytics | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2018-04-23